|
PRELID2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
6.25360000006125E-07 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
2.639500E-02 |
| Stage1-vs-Stage3 |
4.455400E-01 |
| Stage1-vs-Stage4 |
7.176500E-04 |
| Stage2-vs-Stage3 |
2.048300E-02 |
| Stage2-vs-Stage4 |
2.193200E-04 |
| Stage3-vs-Stage4 |
2.149700E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
6.62680021967788E-10 |
| Normal-vs-Asian |
1.62458935193399E-12 |
| Caucasian-vs-AfricanAmerican |
7.952800E-01 |
| Caucasian-vs-Asian |
1.404570E-01 |
| AfricanAmerican-vs-Asian |
5.131200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
8.697800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(81-100Yrs) |
1.73120000002136E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.167600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.224200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.091400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.719800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.503000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.599000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.37669999999924E-05 |
| Classical-VS-Follicular |
1.168810E-01 |
| Classical-VS-Other |
7.409600E-01 |
| Classical-VS-Normal |
1.62458935193399E-12 |
| Tall-VS-Follicular |
4.22039999999901E-05 |
| Tall-VS-Other |
1.804230E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
7.978400E-01 |
| Follicular-VS-Normal |
9.89350046332049E-10 |
| Other-VS-Normal |
7.443300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.060100E-02 |
|
|
